Jane Street
FDMT icon

Jane Street’s 4D Molecular Therapeutics FDMT Stock Holding History

Jane Street’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,694
Closed -$387K – 12002
2026
Q1 		$370K Sell
39,694
-185,209
-82% -$1.61M ﹤0.01% 8755
2025
Q4 		$1.69M Buy
224,903
+107,988
+92% +$1.1M ﹤0.01% 5138
2025
Q3 		$1.02M Sell
116,915
-73,458
-39% -$439K ﹤0.01% 6284
2025
Q2 		$706K Buy
190,373
+49,494
+35% +$174K ﹤0.01% 6285
2025
Q1 		$455K Sell
140,879
-69,945
-33% -$330K ﹤0.01% 7053
2024
Q4 		$1.17M Buy
210,824
+65,312
+45% +$513K ﹤0.01% 5068
2024
Q3 		$1.57M Buy
145,512
+11,987
+9% +$199K ﹤0.01% 4963
2024
Q2 		$2.8M Buy
133,525
+104,014
+352% +$2.61M ﹤0.01% 3918
2024
Q1 		$940K Buy
29,511
+4,016
+16% +$102K ﹤0.01% 5534
2023
Q4 		$517K Sell
25,495
-21,429
-46% -$282K ﹤0.01% 6702
2023
Q3 		$597K Buy
46,924
+5,141
+12% +$86K ﹤0.01% 6006
2023
Q2 		$755K Buy
+41,783
New +$769K ﹤0.01% 5677
2023
Q1 		– Sell
-36,306
Closed -$706K – 9273
2022
Q4 		$806K Buy
+36,306
New +$561K ﹤0.01% 5321

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Jane Street's FDMT Position: Q2 2026 in Review

Jane Street sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 39,694 shares — an estimated $387K sold.

Jane Street first reported a position in FDMT in Q4 2022 and held it in 13 quarters. The position peaked at $2.8M in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Jane Street reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 39,694 4D Molecular Therapeutics shares in Q2 2026, an estimated $387K.
  • Jane Street first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 13 quarters.
  • Jane Street's 4D Molecular Therapeutics position peaked at $2.8M in Q2 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.